803 related articles for article (PubMed ID: 15126373)
41. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
42. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
43. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
44. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
Daood M; Tsai C; Ahdab-Barmada M; Watchko JF
Neuropediatrics; 2008 Aug; 39(4):211-8. PubMed ID: 19165709
[TBL] [Abstract][Full Text] [Related]
45. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246
[TBL] [Abstract][Full Text] [Related]
46. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation.
Petropoulos S; Gibb W; Matthews SG
Brain Res; 2010 Oct; 1357():9-18. PubMed ID: 20709040
[TBL] [Abstract][Full Text] [Related]
47. An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.
Helms HC; Hersom M; Kuhlmann LB; Badolo L; Nielsen CU; Brodin B
AAPS J; 2014 Sep; 16(5):1046-55. PubMed ID: 24934296
[TBL] [Abstract][Full Text] [Related]
48. P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.
Liao MZ; Gao C; Shireman LM; Phillips B; Risler LJ; Neradugomma NK; Choudhari P; Prasad B; Shen DD; Mao Q
Pharmacol Res; 2017 May; 119():61-71. PubMed ID: 28111265
[TBL] [Abstract][Full Text] [Related]
49. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.
Shukla S; Zaher H; Hartz A; Bauer B; Ware JA; Ambudkar SV
Pharm Res; 2009 Feb; 26(2):480-7. PubMed ID: 18841445
[TBL] [Abstract][Full Text] [Related]
50. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
[TBL] [Abstract][Full Text] [Related]
51. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
52. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
53. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
54. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
55. [¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.
Hosten B; Boisgard R; Jacob A; Goutal S; Saubaméa B; Dollé F; Scherrmann JM; Cisternino S; Tournier N
Eur J Pharm Sci; 2013 Nov; 50(3-4):520-5. PubMed ID: 23981334
[TBL] [Abstract][Full Text] [Related]
56. Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier.
Chapy H; Saubaméa B; Tournier N; Bourasset F; Behar-Cohen F; Declèves X; Scherrmann JM; Cisternino S
Br J Pharmacol; 2016 Feb; 173(3):497-510. PubMed ID: 26507673
[TBL] [Abstract][Full Text] [Related]
57. Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.
Vautier S; Milane A; Fernandez C; Chacun H; Lacomblez L; Farinotti R
J Pharm Pharm Sci; 2009; 12(2):199-208. PubMed ID: 19732497
[TBL] [Abstract][Full Text] [Related]
58. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
59. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
60. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
